Lucillia Bezu
Papers
1
Total Citations
129
H-Index
1
About
Dr. Lucillia Bezu is a leading researcher in cancer immunology and oncolytic therapy, with a particular focus on the mechanisms by which anticancer treatments trigger immunogenic cell death (ICD). Her most cited work, "The oncolytic peptide LTX-315 triggers immunogenic cell death" (2016, 129 citations), demonstrates that LTX-315—a cationic amphilytic peptide—preferentially permeabilizes mitochondrial membranes, inducing a partially BAX/BAK1-regulated, caspase-independent necrosis. Crucially, she showed that intratumoral injection of LTX-315 stimulates a robust T lymphocyte-mediated anticancer immune response, establishing a novel link between peptide-based oncolysis and adaptive immunity. This contribution has significant implications for developing therapies that not only kill tumor cells but also provoke systemic immune surveillance. Dr. Bezu’s work has been instrumental in advancing the understanding of how physical and chemical agents can convert dying cancer cells into in situ vaccines. Her research continues to shape the design of next-generation immunotherapies, bridging the gap between direct tumor destruction and long-term immunological memory.
Research Focus
Key Achievements
Top Papers
- 1The oncolytic peptide LTX-315 triggers immunogenic cell death129 citations · 2016